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Abstract
Background: There is no more challenging a group of pharmaceuticals than antimicrobials. With the antibiotic era
came great optimism as countless deaths were prevented from what were previously fatal conditions. Although
antimicrobial resistance was quickly identified, the abundance of antibiotics entering the market helped cement
attitudes of arrogance as the “battle against pestilence appeared won”. Opposite emotions soon followed as many
heralded the return of the pre-antibiotic era, suggesting that the “antibiotic pipeline had dried up” and that our
existing armament would soon be rendered worthless.
Discussion: In reality, humans overrate their ecological importance. For millions of years there has been a balance
between factors promoting bacterial survival and those disturbing it. The first half century of the “antibiotic era” was
characterised by a cavalier attitude disturbing the natural balance; however, recent efforts have been made through
several mechanisms to respond and re-strengthen the antimicrobial armament. Such mechanisms include a variety
of incentives, educational efforts and negotiations. Today, there are many more “man-made” factors that will
determine a new balance or state of ecological harmony.
Conclusion: Antibiotics are not a panacea nor will they ever be inutile. New resistance mechanisms will be
identified and new antibiotics will be discovered, but most importantly, we must optimise our application of
these extraordinary “biological tools”; therein lays our greatest challenge – creating a society that understands
and respects the determinants of the effectiveness of antibiotics.
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Background
The discovery of penicillin brought great hope for the
treatment of infectious diseases. However, two decades
later, in the late 1940s, acceptance, mass production and
distribution led to the advent of the concept with which
we are all now very familiar – antimicrobial resistance
(AMR). As other classes of antibiotics emerged, a similar
pattern ensued from discovery through increasing
utilisation to resistance. Poor infection control practices
in healthcare settings facilitated the transmission of
resistant organisms, amplifying the effect of antimicrobial
usage. The healthcare industry responded with two major
programmes – Infection Control in the 1980s and
Antimicrobial Stewardship in the last decade. These pro-
grams rely on the end user; however, while the importance
of such global programmes cannot be disputed, these ef-
forts alone are inadequate against the emergence of AMR.
If clinicians are to have an antimicrobial arsenal to
treat infectious diseases, a combination of efforts to both
preserve the value of what is currently available and to
promote drug discovery is needed. Preservation of exist-
ing antimicrobials ultimately relies on minimising their
use in all circumstances. In humans, there are many
strategies to support this goal, including the implementa-
tion and adherence to guidelines provided by international
organisations such as the World Health Organization
(WHO) and the Centres for Disease Control and Preven-
tion, by national bodies and individual institutions, as
well as through the implementation of rapid (possibly
point-of-care) diagnostic tests for AMR. Further, infec-
tion prevention activities also need to be implemented
to minimise the need for treatment.
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In addition to direct human ingestion, animal husbandry
is a major setting for antibiotic consumption that allows
indirect human exposure to the same antibiotic or the re-
sistant organisms (or their resistance genes) emerging via
animals farmed as a source of food. The strategies to curb
this are considerably more complex, requiring engagement
of a number of non-medical players less appreciative of
the ramifications of antibiotic misuse.
Drug discovery has suffered from a lack of exploitable
bacterial binding sites, leading to the slow emergence of
truly novel agents. Modifying existing antimicrobial agents
to achieve theoretical benefits is often seen as commer-
cially safer. Many pharmaceutical companies have shifted
towards treatment of chronic conditions in order to lessen
the financial risk. Therefore, this movement needs to be
opposed with financial incentives and better protection
for future and more novel antimicrobial discoveries.
The antibiotic pipeline needs to be restored, but whether
such efforts will be successful remains to be seen.
Along with the excessive morbidity and mortality,
AMR poses a major economic burden, which helps justify
the costs of AMR response programmes. In the United
States (US), mortality from antimicrobial-resistant infec-
tions is reported at 23,000 deaths annually, with costs esti-
mated at US$ 26 billion [1]. In Europe, the annual hospital
death rate is estimated at over 25,000, with costs totalling
more than EUR 900 million [2].
Humankind has enjoyed the capacity to treat bacterial
infections for over 75 years. In this commentary, we
present a number of efforts intended to help maintain
this capacity moving forwards. These efforts could be
regarded as more of a “bundle”, where none will have
significant benefit if implemented in isolation. AMR is a
natural phenomenon – there are behaviours that stimulate
it and responses that minimise it. The fear of “re-entering
the pre-antibiotic era” is as unlikely as the eradication of
antimicrobial-resistant organisms. We do, however, have
some control over where on this spectrum the value of
our antimicrobial armament will sit in the future. While
the development of other classes of therapeutics relies on
building on an existing knowledge base, in the world of
antimicrobials, advances need to be made while simultan-
eously protecting the current therapeutic options from the
very real threats to their effectiveness.
Controlling AMR
Implementation of antimicrobial stewardship
programmes
Bacteria are excellent at evolving mechanisms to counter
the effects of antibacterial agents and this has been the
way since ancient times, long before humans and mod-
ern medicine. Much has been written on the antibiotic
resistosome, which has evolved from environmental
bacteria and competitive pressure from other unicellular
organisms in conjunction with the ability to receive gen-
etic material both vertically (from “parent” bacteria) and
horizontally from other organisms. Confronted with many
mechanisms evident against all antimicrobials, it was time
for a renewed respect for our relationship between micro-
organisms, antimicrobials and resistance mechanisms and
drivers. In the human administration of antibiotics today,
this is called stewardship.
Although the concept of antibiotic stewardship was
raised in the 1980s, it had no validation until a randomised
controlled study demonstrated that antibiotic use could be
significantly reduced without adverse outcomes [3, 4].
Since then, it has grown and evolved into a prospective,
formalised, multidisciplinary programme. Active interven-
tions, such as discontinuing redundant antibiotics, transi-
tioning from parenteral to oral therapy, optimising dose
regimens and de-escalating from broad-spectrum to
pathogen-directed therapies, have been shown to reduce
costs and toxicity and prevent the selection of resistant or-
ganisms [5–7]. While the emergence of antibiotic-resistant
organisms requires at least some antibiotic exposure, the
relationship between the extent of use and resistance is
less clear. It is intuitive that reducing antibiotic use is key
to countering this natural phenomenon; however, social
factors, including government corruption, have been
postulated as more valid [8]. It is likely that corruption
is a surrogate for poor behaviour in terms of stewardship,
infection control, public health and the necessary govern-
ment controls to affect and monitor healthcare and agri-
cultural systems driving the spread of resistant organisms.
This lack of clarity of the benefits of a solitary inter-
vention, such as antibiotic stewardship programmes,
should not deter us from the very likely benefit (and at a
minimum, lack of harm) of it as part of a holistic multi-
pronged response. Although efforts have been made
internationally to encourage such programs, this is still
primarily limited to acute care settings and tertiary cen-
tres where there are infectious disease physicians or
microbiologist champions. However, to optimise future
benefits, programmes must be effective in all healthcare
settings, including outpatients, aged care, peripheral/
rural hospitals, the community and, importantly, animal
husbandry. Stewardship practices should not be limited
to antimicrobials used for treatment, but should include
those used for prophylaxis, which vary considerably and
are not supported by evidence. The role of good stew-
ardship can be undermined when attention is excessively
directed to seemingly more tangible strategies such as
reinforcing the pipeline of new antibiotics. A balanced
approach is required.
Non-prescription antibiotics
Non-prescription, over-the-counter antimicrobial access
occurs worldwide, particularly in Asia and Southern
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Europe [9]. This is associated with frequent adverse
events, masking of underlying infection and a contribution
to the issue of increasing AMR as its use does not take into
account a qualified clinical opinion and local susceptibility
patterns. Although the contribution of non-prescription
antibiotic use to the worldwide spread of resistance is not
known, it has been speculated to play an important role in
producing high levels of resistance in those communities.
In Chile [10] and Korea [11], improved regulation of non-
prescription antibiotics has been associated with improved
resistance profiles. Not only can the consumed antibiotic
be the wrong choice, but there is evidence that the use of
expired [12], counterfeit [13, 14] and inappropriately low
antimicrobial doses [15–17], which are common associa-
tions, contribute further to the risk of treatment failure and
resistance. Self-medication is a potentially important alter-
native to formal consultations, particularly in low-resource
settings; however, in reality, such access to medication with-
out a prescription is usually a cultural and system issue, as
doctors are often available. In most populations, this issue
can be resolved, but not without controversy. The chal-
lenges in changing this practice lie not only in implement-
ing legislation that will prevent the use of over-the-counter
antibiotics but increased awareness through educational
interventions and, most importantly, easy access to
professional help and affordable drugs.
Reducing antibiotic use in animals and agriculture
Agriculture and food animals are important sources of
AMR as they are exposed to enormous quantities of an-
tibiotics and serve as a reservoir of antibiotic-resistance
genes. Antibiotics have been used in animal husbandry,
veterinary medicine and agriculture to prevent, control
and treat infections for over 60 years. Antibiotic use in
growth promotion is, however, controversial. It was dis-
covered that small sub-therapeutic doses of penicillin
and tetracycline could enhance weight gain by about
15–20 %, although the underlying mechanism of this ac-
tion remains unclear [18–21]. Sweden became the first
country to ban antimicrobial use as growth promoters
followed by Denmark and Germany. The implementation
of a European Union-wide ban occurred in 2006 [22]. Par-
tial restriction exists in countries such as Mexico, South
Korea, Taiwan and Hong Kong; however, widespread use of
antimicrobial growth promoters still occur in the majority
of the world. Transmission of resistance occurs through the
food chain, through contact with people working with ani-
mals, such as farmers, and through manure-contaminated
environments. The recent report of plasmid-mediated co-
listin resistance genes found in slaughtered pigs, raw food
and humans highlights the risk of transmission from ani-
mals to humans [23]. Efforts have been made by some
countries, including the US, to phase out the use of antibi-
otics in animal feeds. Regulating and raising awareness and
support amongst farmers, food producers and retailers have
taken place; yet, more still needs to be done globally [24].
There are many possible options for supporting the
concerns of the farming community while reducing
their antimicrobial use. These include establishing stan-
dardised universal surveillance of antibiotic use and re-
sistance, ensuring appropriate training and prudent use
of antibiotics, expanding the range of vaccines available
for veterinary use, using phage therapy (the neutralisation
of foodborne pathogens in animals [25] and control of
plant pathogens [26]), and using predatory bacteria in
combating pathogenic bacteria [27, 28].
Reviving the antibiotic pipeline
Antibiotic discovery was strong from the 1940s to 1960s,
but slowed for some decades until the introduction of
linezolid in 2000 and daptomycin in 2003 [29]. Most
of the early antibiotics were discovered by screening
soil-derived actinomycetes; yet, over time, this source
became exhausted and no longer provided novel com-
pounds or a further understanding of the mechanisms
of action. Efforts have since been redirected to producing
synthetic antibiotics by modification of existing drugs to
produce active analogues, but this has led to limited bene-
fits. The subsequent development of high-tech platforms
based on genomics and combinational chemistry, such as
high-throughput screening and rational drug design, were
employed but failed to identify compounds with effective
antibacterial activity [30]. The number of large multi-
national pharmaceutical companies actively developing
antibiotics declined as a result of this lack of progress in
the field along with the financial risks.
Drug discovery and development is conventionally
driven by financial motivation. For the private industry,
aligning to an antimicrobial programme has more risk
than other pharmacological fields. Taking new drugs to
market requires considerable testing for safety and efficacy
in each indication sought. Once resistance ensues, the
clinical, and therefore commercial, value of the product
falls. In the medical profession, physicians try to limit a
new antibiotic’s utilisation to maintain its clinical value;
however, paradoxically, this affects sales, in effect creating
another disincentive to drug discovery. When these new
drugs are used in infectious disease management they
have a short-term curative application as opposed to drugs
used in the treatment of chronic diseases. It is no wonder
that this “antibiotic pipeline” is weak and requires support
from government and non-government sectors.
Supporting the discovery and development of new
antimicrobial drugs
Recognising the waning value of the antimicrobial arma-
ment, in 2004, the Infectious Diseases Society of America
proposed legislative, regulatory and funding solutions to
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counteract barriers in the development of new antibiotics
[31]. These included tax incentives for development of pri-
ority antibiotics, measured liability protections, revising
existing guidelines for clinical trials involving new antibi-
otics, and supporting public/private partnerships to in-
crease funding. The so-called antibiotic pipeline could not
flourish relying on conventional market forces alone, and
the last decade or so has seen considerable attention to
legislative support (Fig. 1). The extent of these efforts
in supporting drug discovery was unprecedented.
The 10 × ‘20 campaign, launched by the Infectious Dis-
eases Society of America in 2010, called for the develop-
ment and approval of 10 novel antibiotics by 2020 [29].
The Global Action Plan by WHO aims to improve
awareness of AMR, strengthen knowledge through sur-
veillance and research, reduce the incidence of infection,
optimise the use of antimicrobial agents and increase in-
vestment in new drugs, diagnostic tools and vaccines
[32]. The O’Neil Review on Antimicrobial Resistance by
Prime Minister David Cameron in the United Kingdom
[33] and the release of the National Action Plan for
Combating Antibiotic Resistant Bacteria by President
Barack Obama [34], highlight the high level support for
these efforts and augment the global response.
Many other initiatives and collaborations have recently
been established to create new models for antibiotic devel-
opment via incentive strategies. These include the provision
of subsidies to lower antibiotic research costs for drugs with
a large market, high potential sales and low risks. Sharing
of scientific databases would facilitate collaboration be-
tween developers, minimising duplication and facilitating
the dissemination of new information. Funding training
and development of individuals specialising in research and
development of antibiotics is key, as is financial support for
small companies that are likely to produce marketable
products but lack the capital to do so [35–37]. The
European Commission’s Innovative Medicines Initiative
[38] is a large public–private incentive programme sup-
porting the rapid development of effective drugs through
which the New Drugs for Bad Bugs (ND4BB) initiative
[39] and, subsequently, the DRIVE-AB programme [40]
were established with the aim of facilitating antibiotic dis-
covery and development through various collaborations.
Another strategy was to compensate successful devel-
opment as a way to motivate developers. The Generating
Antibiotic Incentives Now Act was ratified in October
2012 by the US government and aimed to incentivize
antibiotic discovery [41]. This included granting an add-
itional 5 years of market exclusivity for antibiotics devel-
oped to treat serious infections, termed the qualified
infectious disease product, and an additional 6 months
for development of a companion rapid diagnostic test.
This bill also entitled the new drug to priority review
and fast-track approval, which in turn committed the
Food and Drug Administration (FDA) to review its clin-
ical trial guidelines and review processes. In addition, a
streamlined clinical trial process for novel antibiotics,
the Limited Population Antibacterial Drug approval,
allows potential drugs to be studied via smaller, faster
and less expensive trials [42]. Following this, a proposed
US bill, the 21st Century Cures Act, offers qualified anti-
biotics Limited Population Antibacterial Drug approval
and the option of transferable market exclusivity for up
to 12 months, where the purchasers are required to do-
nate a portion of the returns to AMR research and patient
access programmes [43].
Fig. 1 The antibiotics timeline since 2000. Since 2000, only a small number of antibiotics have been approved (below the timeline). Recently
efforts have broadened to enhance the potential pipeline and also to protect the antibiotics currently available (above the timeline), by incentives
and legislation
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Perhaps a more well-rounded model is the WHO’s
Global Consortium [44, 45], which provides support at
the drug discovery stage via an open source platform as
well as grants for academics. It aims to lower develop-
ment costs and risk using patent buy-outs of successfully
developed antibiotics (which facilitates antibiotic stew-
ardship and negates the need for excessive marketing),
funding of clinical trials and advance purchase commit-
ments for generic distribution.
Additionally, many business models and incentive
strategies have been proposed, with some placing em-
phasis on investment at the beginning of drug develop-
ment while others reward only successful development
of a drug [46]. Nevertheless, a successful package not
only requires the creation of a supportive environment
for investment that increases profitability and aligns both
public and private priorities, but should also address pub-
lic health objectives such as promoting antibiotic steward-
ship and improving patient access to new (potentially
expensive) antibiotics.
What’s new in the pipeline?
Since the approval of telavancin in 2009 and ceftaroline
in 2010, five new antibiotics have been approved by the
FDA, three of which have mainly gram-positive activity
and two directed against gram-negative pathogens. Ori-
tavancin and dalbavancin are long-acting, synthetic lipo-
glycopeptides with activity against methicillin-resistant
Staphylococcus aureus and vancomycin-resistant Entero-
coccus, and are approved for treatment of acute bacterial
skin and skin structure infections [47–49]. Tedizolid,
an oxazolidinone-class antibiotic similar to linezolid, is
licensed for treatment of these infections [50], with
treatment for other indications underway, including
hospital-acquired pneumonia. While these new drugs
have the advantage of being utilised in the outpatient
setting, thus avoiding prolonged intravenous use and
length of hospital stay, they are still costly and questions
remain as to their utility in the treatment of more serious
clinical infections such as bacteraemia, endocarditis,
osteomyelitis and device-related infections. Ceftolozane/
tazobactam and ceftazidime/avibactam are approved for
treatment of complicated intra-abdominal and urinary
tract infections; nevertheless, the latter is only approved
for use in patients with limited or no treatment options as
it was the first drug to go through the recommended
regulatory pathway and deemed to be an “unmet medical
need drug” [51–53]. Both antibiotics have activity
against extended spectrum beta-lactamases, AmpC
producers and multi-drug resistant Pseudomonas aeru-
ginosa, but only ceftazidime/avibactam has activity
against Class A carbapenemases.
In May 2016, the Pew Charitable Trust, which main-
tains a regularly updated antibiotic pipeline, described
37 new antibiotics in development, of which 11 were in
phase I clinical trials, 13 in phase II and 13 in phase III
[54]. About a third of these have the potential to treat
infections caused by Enterococcus faecium, Staphylococcus
aureus, Klebsiella pneumoniae, Acinetobacter baumannii,
Pseudomonas aeruginosa and Enterobacter spp (ESKAPE
pathogens), and just over a third have activity against
drug-resistant gonorrhoea, Clostridium difficile and
carbapenem-resistant Enterobacteriaceae, which are
pathogens considered an “urgent threat” by the Centres
for Disease Control and Prevention [1]. Of drugs in phase
III, only about 60 % will typically reach FDA approval level
and only about half of these are active against gram-
negative pathogens. Notably, none have promising activity
against carbapenem-resistant Acinetobacter sp. or the
Class D metallo-beta-lactamases (e.g. NDM-1) [54]. Of the
37 antibiotics, very few have a novel mechanism of action
and none of these are yet in phase III studies. Nonetheless,
there is reason for optimism in both the short and
long term.
Bacteriophage treatment is a largely untested approach
to antibacterial therapy and represents a revival of a previ-
ous option. These viruses infect and rapidly kill specific
target bacteria. Nevertheless, none are in therapeutic prac-
tise although many are in development and at various
stages of clinical trials [55]. Bacteriophages may prove to
be novel antimicrobial agents with potential use in decolon-
isation or treatment of infection alone or in association with
conventional antibiotics, and there is also specific potential
for their use in infections complicated by biofilm formation.
The side effect profile needs to stand the test of time, but
the few studies to date suggest a good safety profile [56].
A renewed hope for antibiotic discovery?
In January 2015, a group of scientists from Northeastern
University, MA, described their discovery of an antibiotic,
teixobactin, with a completely different chemical scaffold to
that of existing antibiotics. It has gram-positive activity,
which works through binding to precursors of bacterial cell
wall polymers and appears to have no inducible resistance.
This discovery involved a novel technology called iChip
[57], a miniaturised, multichannel device that allowed
antibiotic-producing soil bacteria to be cultivated and iden-
tified in their natural environment. Scouring the soil for
new antimicrobial molecules has proven to be extremely
challenging in the last decade as soil microorganisms
cannot be grown under traditional laboratory conditions.
This innovation can hopefully be applied to identify
promising molecules with novel mechanisms of action.
Improving affordability and improving patient
access to antibiotics
When a new antibiotic reaches the end of the arduous
pipeline and is registered, the traditional patent-based
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pharmaceutical model grants developers market exclu-
sivity for a number of years, following which generic
manufacturers are permitted development and market-
ing opportunities to the drug. During these early years
with the patent in place, the pharmaceutical organisation
has a window period to obtain financial returns for the
research and development, clinical trials and notoriously
expensive marketing, as well as shareholder profit; they
control the market geographically and they control price.
Most patients cannot benefit from drugs that are not
distributed globally and financial returns are not usually
found in low- and middle-income countries. In fact, most
patients in high-income countries will struggle with meet-
ing the costs as individuals; drugs not yet recognised in
national pharmaceutical benefit systems or by insurers
may lead to excessive costs for individuals even in these
countries.
It is a “double-edged sword”, where we wish to im-
prove access, yet not to the point where excessive use
drives high levels of resistance. Any programme that im-
proves access to individuals in need should build-in
measures that minimise inappropriate use. The current
model potentially creates incentive to encourage any
consumption of the antibiotic, but only to those individ-
uals and countries that can pay. In the last decade or so,
several systems have provided remarkable contributions
to access in low- and middle-income countries on a large
scale, including the Global Fund (for malaria, tuberculosis
and HIV), The Presidents Emergency Fund for AIDS Re-
lief (PEPFAR) and the Global Alliance for Vaccines and
Immunisation (GAVI). Ideally, similar efforts in the name
of antibiotic access could ensue via negotiation and
bulk purchasing or via subsidy. The crucial effort lies
in delinking profits from sales volume. The scale of the
antibiotic issue is different and the situation more com-
plex, but some efforts have been initiated; examples in-
clude the Antibiotic Health Impact Fund, Antibiotics as
Public Goods, and the Rewarding Antibiotic Development
and Responsible Stewardship Programme, where antibi-
otics could be offered at a marginal cost and overall profit-
ability of projects is tied to global health impact [46, 58].
Whilst still providing developers with a concrete return, it
removes the motivation to oversupply the market, incenti-
vises developers to distribute their new antibiotics, and
facilitates access to those who need them most. Other
strategies include patent buy-outs to successfully devel-
oped antibiotics and sales of a license for unlimited access
to antibiotics at a small cost, hence allowing fair distribu-
tion, increased affordability and equitable access [58].
Raising awareness and changing prescribing
patterns and behaviour
There is no doubt that inappropriate antibiotic use is a
significant contributor to the emergence of resistance
[59, 60]. It has been suggested that 20–50 % of prescribing
is unnecessary. In primary care, antibiotics are frequently
Fig. 2 The balance that will determine the effectiveness of antimicrobials as a class. The value of the antimicrobial armament in the future is
dependent on numerous opposing forces. Factors on the left of the scale represent those diminishing the value while those on the right aspire
to counter these. The ultimate worth of antimicrobials in the future will be realised in how these opposing forces balance out
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prescribed for upper respiratory tract symptoms and the
treatment of asymptomatic bacteriuria is associated with a
higher prevalence of resistant organisms [61–64]. The pre-
scription and use of antibiotics is influenced by a complex
interplay of knowledge and attitudes of the prescriber and
patient (and in the case of animal husbandry, the farmer).
Patients who expect a prescription are more likely to get
one [65, 66]. Many doctors would admit that patients’
expectations, peer pressure, fear of litigation, poor know-
ledge of microbiology and underutilisation of available
guidelines play a role in driving poor antibiotic use
[62, 67]. Few clinicians see the bigger picture, the anti-
biograms, the national epidemic curves, etc.; however, all
prescribers and users are contributors to the evolving
quantum of multidrug-resistant infections. There needs to
be an increased awareness that the imprudent use of anti-
biotics does not usually exert its effect at an individual
level, but to the society as a whole, with serious public
health implications. A recent WHO assessment revealed
that there is a lack of awareness among both the public
and healthcare workers in this matter [68]. Several inter-
ventions to improve antibiotic use targeting both the pub-
lic as well as healthcare providers, particularly multimodal
campaigns, have shown positive outcomes in terms of
adherence to guidelines and reduction of inappropriate
prescription [69–71]. However, it remains unclear whether
the effectiveness of these campaigns as well as the change
in practice and behaviour are sustainable. Multifaceted
mass media and educational campaigns targeting both the
public and healthcare professionals, but culturally tailored
to the particular community, should be held with active
engagement of all levels of authority. This should be per-
formed in a coordinated and comprehensive manner that
addresses all aspects of behaviour such as capability, op-
portunity and motivation [72]; changing health behaviour
is difficult and requires significant and sustained commit-
ment and investment.
Conclusion
Antibiotics are unique therapeutics and a human re-
source. They are the only drug class that, when used in
an individual, it can affect others. Their misuse has re-
sulted in a shift in the ecological balance between resistant
and susceptible strains in the flora of humans, animals
and the environment, and there are several determinants
of where the balance will settle (Fig. 2). As healthcare pro-
viders, we hope for sensitive strains and highly effective
antibiotics. The best outcome for the most favourable
balance lies in a multisystem approach to the handling
of antibiotics.
The urgent call to curb AMR requires efforts at all
levels – governments, healthcare providers, pharmaceutical
companies, veterinary and agriculture sectors, and the
general public. We can be very optimistic about current
deliberate efforts, including the expansion of stewardship
in human medicine, animals and agriculture, changing
regulations, and creating incentives that promote the
discovery of truly novel drugs, as well as ensuring global
access to antibiotics. Global society as a collective must
share the same perspective of the issues and the vision re-
quired to work towards maintaining a strong antimicrobial
armament. Antibiotics are a unique biological tool that
demands respect, as does any form of Nature. Humans
have only recently begun to influence the ecologic bal-
ance between antibacterials, bacteria and the resistance
mechanisms they display. There is an increasing current
understanding that we can favourably restore the balance
that preserves and enhances the value of this critical thera-
peutic class.
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